Inhibition of GART by siRNA-mediated depletion or lometrexol (LMX) inhibitor preferentially reduced cell proliferation and induced ERα degradation in ERα-positive IDC cell lines belonging to the LumA clinical surrogate class of breast cancer. This evidence concerns the gene ESR1 and breast cancer.